Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib as Adjuvant to Radioiodine in Thyroid Carcinoma
NCT00887107Phase 2Completed
- Sponsor
- Leiden University Medical Center
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in Differentiated Thyroid Carcinoma (DTC), sponsored by Leiden University Medical Center. Primary endpoints: Proportion of patients with a favorable response at 6 months, Reinduction of RaI uptake by RaI scintigraphy at 6 months and 2 more. Started Oct 2007; status: completed.
02
Drugs
sorafenib
03
Conditions
Differentiated Thyroid Carcinoma (DTC)
Beyond the preview
Go deeper on NCT00887107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00887107.